Polycythemia vera is a chronic myeloproliferative disorder characterized by increased red blood cells, blood volume, and often leukocytosis and thrombocytosis. The bone marrow is hypercellular with increased myeloid, erythroid, and megakaryocyte cells. A common genetic mutation involves the JAK2 gene, resulting in continuously activated tyrosine kinase signaling and driving cell proliferation. A JAK2 V617F mutation is present in the majority of polycythemia vera patients.

1. Polycythemia Vera .

7. Genetic abnormalities in CMPDs Disease Specific abnormalitis Reccuring, non specific cytogenetic abnormalities 1. Chronic myelogenous leukemia BCR / ABL, t(9;22) +Ph, +8, +9 2. Polycythemia Vera JAK2 V617F +8, +9, del(20q), del(13q) 3. Essential Thrombocythemia JAK2 V617F +8, del(13q) 4. Chronic Idiopathic Myelofibrosis. JAK2 V617F +8, del(20q), del(7q), del(13q) 5. Chronic Eosinophilic Leukemia +8, t(5;12), FIP1L1-PDGFRA 6. Systemic Mastocytosis FIP1L1-PDGFRA, KIDT816V 7. Chonic Neutrophilic Leukemia +8, +9, del(20q), del(11q14)

9. .

11. Involvement of Janus Kinases in Cytokine Signal Transduction (Panel A) and Structural Map of Janus Kinase 2 (Panel B)

14. Thank you